Faculty of 1000 to launch open access publishing venture

Friday, February 17, 2012 01:50 PM

Faculty of 1000 (F1000) is set to launch F1000 Research, a new fully open access publishing program across biology and medicine, later this year.

The program will address the major issues afflicting scientific publishing today: timely dissemination of research, peer review and sharing of data. Diverging from traditional journal publishing, F1000 Research will offer immediate publication; open, post-publication peer review; open revisioning of work including ongoing updates; and encouragement of raw data deposition and publication.

In addition, F1000 Research will accept a broad range of article formats and will encourage content types now routinely rejected, such as negative results, case studies, thought experiments, preliminary analyses and incomplete data sets.

“The open access model has addressed effectively the issue of inadequate access to research findings,” Vitek Tracz, chairman and founder of F1000. “It did not address the major issues around communicating the research finding: the delays in access, the inadequacies of peer review and the complexities of data publishing. It is up to collaboration between researchers and publishers to come up with a solution, and we are determined to be a part of it.”

Dr. Rebecca Lawrence, who is leading the project at F1000, added, “Many questions remain as we fine tune F1000 Research to break new ground in scholarly publishing. We therefore invite those working in the bioresearch community, institutions, funders, data centers and repositories, and data mining and informatics groups to join us in open discussion and debate about these many outstanding issues—via the RSS feed or by Twitter: @F1000Research.”

F1000 was conceived in 2002 as a collaboration of 1000 international faculty members. It identifies and evaluates the most important articles in biology and medical research publications.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs